Andrei Reshetnickov graduated from Moscow Institute of Fine Chemical Technology, Department of Biotechnology, and from Moscow State Linguistic University (English department) in 1995. Since 1995 until 1999 he took his Ph.D. course in Bioorganic chemistry and chemistry of physiologically active and natural compounds at Moscow State Academy of Fine Chemical Technology. Since 1993 he worked in the Russian Academy of Medical Sciences Institute of biomedical chemistry, in the laboratory of organic chemistry as a laboratory assistant, then since 1995, as a junior research chemist, and finally, since 1999 until 2000 as a research chemist. In 2000 he co-founded an enterprise named RADA-PHARMA Co. Ltd. to search for novel pharmaceutical agents for photodynamic therapy and provide for their investigation up to the complete pharmaceutical approval of selected compounds. Dr. Reshetnickov was the General manager of the company in 2000-2003. One of the developments is a drug substance named "Radachlorin". The process for its manufacturing was patented in March, 2001 in Russia, and then worldwide. In June, 2005 Radachlorin was approved in Russia on the protocol of skin cancer photodynamic therapy. Dr. Reshetnickov has been RADA-PHARMA Co. Ltd. Director R&D since December, 2002.